Норвешка - Норвешки - Statens legemiddelverk

eli lilly norge as - insulin, human - injeksjonsvæske, suspensjon i ferdigfylt penn - 100 ie/ ml

Европска Унија - Норвешки - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porfyrier, nedsatt - ulike alimentary tract and metabolism products - behandling av akutt hepatisk porfyri (ahp) i voksne og ungdom i alderen 12 år og eldre.

Европска Унија - Норвешки - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulin lispro - sukkersyke - legemidler som brukes i diabetes - behandling av diabetes mellitus hos voksne, ungdom og barn i alderen 1 år og over. behandling av diabetes mellitus hos voksne.

Европска Унија - Норвешки - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - andre alimentary tract and metabolism products, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Европска Унија - Норвешки - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipid modifiserende midler - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Европска Унија - Норвешки - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaksiner - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Европска Унија - Норвешки - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - vekst - hypofysiske og hypotalamiske hormoner og analoger - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Европска Унија - Норвешки - EMA (European Medicines Agency)

dynavax gmbh - hepatitt b overflate antigen - hepatitt b - vaksiner - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Европска Унија - Норвешки - EMA (European Medicines Agency)

tetris pharma b.v - glucagon - sukkersyke - bukspyttkjertelen hormoner, hormoner glycogenolytic - ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Европска Унија - Норвешки - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuri, paroksysmal - immunsuppressive - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.